Description:
Study BT-CL-PGG-CRC1031 is a Phase 3, open-label, randomized, multi-center study. Qualified
subjects, who have KRAS wild type (WT) colorectal cancer will be randomized in a 2:1 ratio to
treatment with either Imprime PGG and cetuximab or cetuximab alone. Subjects will be dosed
until progression or discontinuation for some other reason. Efficacy will be assessed via
Response Evaluation Criteria in Early Tumors 1.1 (RECIST 1.1); computed tomography (CT) scans
will be conducted every 6 weeks. Safety, pharmacokinetics (PK), quality of life, and
biomarker parameters will also be assessed.
Title
- Brief Title: Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
- Official Title: A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Clinical Trial IDs
- ORG STUDY ID:
BT-CL-PGG-CRC1031
- NCT ID:
NCT01309126
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Imprime PGG + cetuximab | Imprime PGG, Cetuximab (Erbitux) | Arm 1: Imprime PGG + cetuximab |
Cetuximab | Cetuximab (Erbitux) | Arm 2: cetuximab |
Purpose
Study BT-CL-PGG-CRC1031 is a Phase 3, open-label, randomized, multi-center study. Qualified
subjects, who have KRAS wild type (WT) colorectal cancer will be randomized in a 2:1 ratio to
treatment with either Imprime PGG and cetuximab or cetuximab alone. Subjects will be dosed
until progression or discontinuation for some other reason. Efficacy will be assessed via
Response Evaluation Criteria in Early Tumors 1.1 (RECIST 1.1); computed tomography (CT) scans
will be conducted every 6 weeks. Safety, pharmacokinetics (PK), quality of life, and
biomarker parameters will also be assessed.
Detailed Description
Study BT-CL-PGG-CRC1031 is a Phase 3, open-label, randomized, multi-center study. Qualified
subjects, who have KRAS WT colorectal cancer will be randomized in a 2:1 ratio to either:
Arm 1: Imprime PGG and cetuximab or Arm 2: Cetuximab
Approximately 795 subjects will be randomized into the study. Dosing will occur in 6-week
cycles. Imprime PGG will be dosed at 4 mg/kg and will be administered weekly in each cycle
(Weeks 1-6/Days 1, 8, 15, 22, 29, and 36) preceding the administration of cetuximab (Arm 1
only). The initial cetuximab dose (both arms) will be 400 mg/m2 on Cycle 1/Day 1 and
subsequent doses will be 250 mg/m2 administered weekly in each cycle (Weeks 1-6/Days 1, 8,
15, 22, 29, and 36).
Subjects will be dosed until progressive disease (PD) per RECIST 1.1 or discontinuation of
study drug for other reasons; e.g., safety. Following completion of the treatment period of
the study, subjects will be monitored for survival until death or loss to follow-up. Tumor
measurements and determination of tumor responses will be evaluated according to RECIST 1.1.
Safety, PK, quality of life, and biomarker parameters will also be assessed.
Trial Arms
Name | Type | Description | Interventions |
---|
Arm 1: Imprime PGG + cetuximab | Experimental | Biological/Vaccine + Drug | |
Arm 2: cetuximab | Active Comparator | Drug | |
Eligibility Criteria
Inclusion Criteria:
1. Is >18 years old;
2. Has recurrent or metastatic carcinoma of the colon or rectum with documented
histological or cytological confirmation;
3. Must be KRAS WT;
4. Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a
target lesion according to RECIST 1.1;
5. Has never received cetuximab or panitumumab, and has not received any treatment for
colorectal cancer within 30 days prior to the first dose of study treatment under this
protocol;
6. Has an Eastern Cooperative Oncology Group (ECOG) score of 0-1, with a life expectancy
of >3 months;
7. Has received at least 2 prior chemotherapeutic regimens for colorectal cancer;
8. Has adequate bone marrow reserve as evidenced by:
- Absolute neutrophil count ≥1,500/μL
- Platelets ≥100,000/μL;
9. Has adequate renal function as evidenced by serum creatinine ≤2.5 × the upper limit of
normal (ULN) for the reference lab;
10. Has adequate hepatic function as evidenced by:
- Aspartate aminotransferase ≤3 × ULN for the reference lab (≤5 × ULN for subjects
with known hepatic metastases)
- Alanine aminotransferase ≤3 × ULN for the reference lab (≤5 × ULN for subjects
with known hepatic metastases)
- Bilirubin <1.5 mg/dL or direct bilirubin <1.0 mg/dL
- Serum Albumin >3.0 gm/dL
11. Has read, understood and signed the informed consent form (ICF) approved by the
Independent Review Board/Independent Ethics Committee (IRB/IEC); and
12. If the subject is a woman of childbearing potential or a fertile man, he/she must
agree to use an effective form of contraception during the study and for 60 days
following the last dose of study drug (an effective form of contraception is
abstinence, a hormonal contraceptive, or a double-barrier method).
Exclusion Criteria:
1. Has a known hypersensitivity to cetuximab, murine proteins, or any component of
cetuximab;
2. Has a known hypersensitivity to baker's yeast or has an active yeast infection;
3. Has had previous exposure to Betafectin® or Imprime PGG;
4. Has an active, uncontrolled infection;
5. Has known untreated or symptomatic brain metastases;
6. Had a second malignancy within the previous 5 years, except for basal cell carcinoma,
cervical intra-epithelial neoplasia or treated prostate cancer with a
prostate-specific antigen (PSA) of <2.0 ng/mL;
7. Has known human immunodeficiency virus or acquired immune deficiency syndrome,
hepatitis B, hepatitis C, connective tissue disease, or other clinical diagnosis,
ongoing or intercurrent illness that in the Investigators opinion should preclude the
subject from participation;
8. If female, is pregnant or breast-feeding;
9. Is receiving concurrent standard and/or investigational anti-cancer therapy or has
received such therapy within a period of 30 days prior to the first scheduled day of
dosing (investigational therapy is defined as treatment for which there is currently
no regulatory-authority-approved indication); or
10. Has previously received an organ or progenitor/stem cell transplant.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Overall Survival (OS) |
Time Frame: | 18 months |
Safety Issue: | |
Description: | |
Secondary Outcome Measures
Measure: | Progression Free Survival (PFS) |
Time Frame: | 18 months |
Safety Issue: | |
Description: | |
Measure: | Rate of complete response (CR) |
Time Frame: | 18 months |
Safety Issue: | |
Description: | |
Measure: | Rate of partial response (PR) |
Time Frame: | 18 months |
Safety Issue: | |
Description: | |
Measure: | Rate of overall response (CR + PR) |
Time Frame: | 18 months |
Safety Issue: | |
Description: | |
Measure: | Safety and tolerability of the dosing regimen as measured by the incidence and severity of adverse events observed in study participants |
Time Frame: | 18 months |
Safety Issue: | |
Description: | |
Measure: | Sparse pharmacokinetic profile of Imprime PGG will be determined to expand current Imprime PGG PK data |
Time Frame: | 18 months |
Safety Issue: | |
Description: | Samples for sparse PK will be taken at specified times on Cycle 1/Day 1 in the first 30 available subjects randomized to Arm 1 (Subjects 1-30). Samples will be collected, at multiple times, in the next 60 subjects randomized to Arm 1 who reach Cycle 2/Day 1 of dosing (subjects 31-90). Additionally, any subject after the first 90 subjects (subjects 91-795) who have a screening/baseline calculated creatinine clearance (based on age, weight and serum creatinine) of <60 mL/minute will have sparse PK samples collected. |
Measure: | Change in Quality of Life |
Time Frame: | 18 months |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 3 |
Primary Purpose: | Interventional |
Overall Status: | Terminated |
Lead Sponsor: | Biothera |
Trial Keywords
- Colorectal Cancer
- KRAS Wild Type
- Imprime PGG
- Cetuximab
- Phase 3
- Efficacy
- Safety
- Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Last Updated
July 13, 2017